Shandong Xinhua Pharmaceutical Company Limited Class A

Shandong Xinhua Pharmaceutical Co Ltd's next confirmed earnings release is scheduled for October 28, 2026.

As of March 31, 2026, Shandong Xinhua Pharmaceutical Co Ltd has 178.60M shares outstanding.

As of March 31, 2026, Shandong Xinhua Pharmaceutical Co Ltd maintains a current ratio of 1.76, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.39, indicating elevated leverage, while an interest coverage ratio of 9.99 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Co Ltd posted a return on equity (ROE) of 6.60, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.09 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.77, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.24, useful for judging operating efficiency across full business cycles. The company generates approximately 180,605.80 in revenue per employee across its workforce of 7,268.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.90 indicates how many times Shandong Xinhua Pharmaceutical Co Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Co Ltd recorded 11.78M in income tax expense. That works out to an effective tax rate of 18.67, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 63.08M, leaving 49.49M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on July 10, 2026, Shandong Xinhua Pharmaceutical Co Ltd's stock has declined approximately 0.49% over the past 52 weeks.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Co Ltd generated 1.31B in revenue and converted that into 49.49M in net income, yielding earnings per share of 0.40. EBITDA reached 63.13M, while operating income came in at 74.91M.

As of March 31, 2026, Shandong Xinhua Pharmaceutical Co Ltd holds 185.08M in cash and equivalents against 206.03M in total debt, resulting in a net debt position of 17.47M. Total book value stands at 775.61M, with working capital of 254.45M providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Co Ltd posted a gross margin of 18.98, reflecting its pricing power and cost economics. The operating margin of 5.71 and net profit margin of 3.77 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Shandong Xinhua Pharmaceutical Co Ltd paid dividends of 0.04 per share. The dividend payout ratio of 9.93 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Shandong Xinhua Pharmaceutical Co Ltd's most recent stock split took place on July 23, 2018 with a 10:13 split ratio.